Zoetis (ZTS) Accumulated Expenses (2012 - 2026)
Zoetis' (ZTS) quarterly Accumulated Expenses came in at $239.0 million in Q1 2026, down 17.87% year-on-year from $291.0 million in Q1 2025, and down 40.4% on a QoQ basis from $401.0 million in Q4 2025.
Zoetis (ZTS) Accumulated Expenses (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Accumulated Expenses data on file, last reported at $239.0 million in Q1 2026.
- On a quarterly basis, Accumulated Expenses fell 17.87% year-over-year to $239.0 million in Q1 2026; TTM through Mar 2026 was $239.0 million, a 17.87% decrease from a year earlier, with the FY2025 full-year figure at $401.0 million, down 46.25% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $239.0 million, down from $401.0 million in the prior quarter.
- Over the last five years, Accumulated Expenses for ZTS reached as high as $746.0 million in Q4 2024 and fell as low as $232.0 million in Q1 2023.
- Historically, Accumulated Expenses has averaged $340.5 million across 5 years, with a median of $284.0 million in 2023.
- Across the five-year window, Accumulated Expenses soared 95.29% in 2024 and sank 46.25% in 2025, its largest moves.
- Year by year, Accumulated Expenses stood at $682.0 million in 2022, then slumped by 43.99% to $382.0 million in 2023, then surged by 95.29% to $746.0 million in 2024, then sank by 46.25% to $401.0 million in 2025, then tumbled by 40.4% to $239.0 million in 2026.
- Per Business Quant data, the three most recent Accumulated Expenses figures were $239.0 million in Q1 2026, $401.0 million in Q4 2025, and $337.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 239.00 Mn |
| Dec 31, 2025 | 401.00 Mn |
| Sep 30, 2025 | 337.00 Mn |
| Jun 30, 2025 | 293.00 Mn |
| Mar 31, 2025 | 291.00 Mn |
| Dec 31, 2024 | 746.00 Mn |
| Sep 30, 2024 | 335.00 Mn |
| Jun 30, 2024 | 276.00 Mn |
| Mar 31, 2024 | 272.00 Mn |
| Dec 31, 2023 | 382.00 Mn |
| Sep 30, 2023 | 284.00 Mn |
| Jun 30, 2023 | 247.00 Mn |
| Mar 31, 2023 | 232.00 Mn |
| Dec 31, 2022 | 682.00 Mn |
| Sep 30, 2022 | 257.00 Mn |
| Jun 30, 2022 | 237.00 Mn |
| Mar 31, 2022 | 278.00 Mn |
| Dec 31, 2021 | 710.00 Mn |
| Sep 30, 2021 | 314.00 Mn |
| Jun 30, 2021 | 239.00 Mn |